(NASDAQ: PEPG) Pepgen's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Pepgen's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast PEPG's revenue for 2027 to be $782,655,769, with the lowest PEPG revenue forecast at $782,655,769, and the highest PEPG revenue forecast at $782,655,769. On average, 2 Wall Street analysts forecast PEPG's revenue for 2028 to be $1,153,714,373, with the lowest PEPG revenue forecast at $778,732,682, and the highest PEPG revenue forecast at $1,528,696,063.
In 2029, PEPG is forecast to generate $3,610,383,869 in revenue, with the lowest revenue forecast at $3,226,084,848 and the highest revenue forecast at $3,994,682,890.